Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Ongoing post-approval monitoring

1 evidence topic · 1 source

Post-approval monitoring requirements

Not applicable.